Breakthrough to Fight Antibiotic Resistance: The Biggest Threat of 21st Century

The Breakthrough Fighting One of The Biggest Threats of 21st Century ... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe A Message from i2i Marketing Group, LLC Dear Reader, Antibiotic resistance is possibly the biggest health crisis of the 21st century. Recent statistics reveal that antibiotic-resistant "superbugs" claim at least 700,000 lives globally each year. If left unchecked, these superbugs could kill up to 10 million people annually by 2050. That would make them a leading cause of death, surpassing heart disease and even cancer. Scientists worldwide are racing to find a solution. And a small team of researchers might have discovered one... A tiny company, in partnership with McMaster University, has developed a revolutionary technology that repels these deadly pathogens by 98%. McMaster University has a history of success - their recent venture was acquired for $2.4 billion. It could be the key to solving the superbug crisis and the next target of a major acquisition. Click here to discover more about this potentially life-saving breakthrough. Trust me, you don't want to miss out on this one.

Thank you for subscribing to The Early Bird, MarketBeat's 7:00 AM newsletter that covers stories that will impact the stock market each day.   This message is a paid advertisement sent on behalf of i2i Marketing Group, LLC, a third-party advertiser of The Early Bird and MarketBeat.     This message is a paid advertisement for FendX Technologies Inc. (FDXTF:OTCQB, FNDX:CSE, E8D:FSE) from i2i Marketing Group, LLC and Investing Insider. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $4,500. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either i2i Marketing Group, LLC or Investing Insider. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding FendX Technologies Inc. (FDXTF:OTCQB, FNDX:CSE, E8D:FSE) on Investing Insider' website for additional information about the relationship between Investing Insider and FendX Technologies Inc. (FDXTF:OTCQB, FNDX:CSE, E8D:FSE).     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you no longer wish to receive email from The Early Bird, you can unsubscribe.   © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.